These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
534 related articles for article (PubMed ID: 25588160)
1. Combination of SF1126 and gefitinib induces apoptosis of triple-negative breast cancer cells through the PI3K/AKT-mTOR pathway. Deng M; Wang J; Chen Y; Zhang L; Liu D Anticancer Drugs; 2015 Apr; 26(4):422-7. PubMed ID: 25588160 [TBL] [Abstract][Full Text] [Related]
2. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma. Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of RPTOR overcomes resistance to EGFR inhibition in triple-negative breast cancer cells. You KS; Yi YW; Kwak SJ; Seong YS Int J Oncol; 2018 Mar; 52(3):828-840. PubMed ID: 29344641 [TBL] [Abstract][Full Text] [Related]
4. Piperlongumine, an alkaloid causes inhibition of PI3 K/Akt/mTOR signaling axis to induce caspase-dependent apoptosis in human triple-negative breast cancer cells. Shrivastava S; Kulkarni P; Thummuri D; Jeengar MK; Naidu VG; Alvala M; Redddy GB; Ramakrishna S Apoptosis; 2014 Jul; 19(7):1148-64. PubMed ID: 24729100 [TBL] [Abstract][Full Text] [Related]
5. [Effect of autophagy inhibitor combined with EGFR inhibitor on triple-negative breast cancer MDA-MB-468 and MDA-MB-231 cells]. Liu ZY; He KW; Song XG; Wang XZ; Zhuo PY; Wang XW; Ma QH; Huo ZJ; Yu ZY Zhonghua Zhong Liu Za Zhi; 2016 Jun; 38(6):417-24. PubMed ID: 27346398 [TBL] [Abstract][Full Text] [Related]
6. Dual PI3K-BRD4 Inhibitor SF1126 Inhibits Colorectal Cancer Cell Growth in Vitro and in Vivo. Qin AC; Li Y; Zhou LN; Xing CG; Lu XS Cell Physiol Biochem; 2019; 52(4):758-768. PubMed ID: 30933440 [TBL] [Abstract][Full Text] [Related]
7. [Molecular mechanisms of resistance to phosphatidyl inositol 3-kinase inhibitors in triple-negative breast cancer cells]. Zhang WL; Ma WJ; Chen S; Wu XZ; Zhang HR; Zhang JH Zhonghua Zhong Liu Za Zhi; 2016 Aug; 38(8):578-88. PubMed ID: 27531477 [TBL] [Abstract][Full Text] [Related]
8. Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness. De P; Sun Y; Carlson JH; Friedman LS; Leyland-Jones BR; Dey N Neoplasia; 2014 Jan; 16(1):43-72. PubMed ID: 24563619 [TBL] [Abstract][Full Text] [Related]
9. [Combined inhibition of PI3K and MEK has synergistic inhibitory effect on the proliferation of cisplatin-resistant ovarian cancer cells]. Liu Y; Chen X; Luo Z Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jun; 30(6):592-6. PubMed ID: 24909280 [TBL] [Abstract][Full Text] [Related]
10. Polyphyllin II Restores Sensitization of the Resistance of PC-9/ZD Cells to Gefitinib by a Negative Regulation of the PI3K/Akt/mTOR Signaling Pathway. Zheng R; Jiang H; Li J; Liu X; Xu H Curr Cancer Drug Targets; 2017; 17(4):376-385. PubMed ID: 28093061 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38. Gohr K; Hamacher A; Engelke LH; Kassack MU BMC Cancer; 2017 Nov; 17(1):711. PubMed ID: 29100507 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells. Block M; Gründker C; Fister S; Kubin J; Wilkens L; Mueller MD; Hemmerlein B; Emons G; Günthert AR Int J Oncol; 2012 Nov; 41(5):1845-54. PubMed ID: 22922893 [TBL] [Abstract][Full Text] [Related]
13. [Study of gambogenic acid-induced apoptosis of melanoma B16 cells through PI3K/Akt/mTOR signaling pathways]. Cheng H; Zhang X; Su JJ; Li QL Zhongguo Zhong Yao Za Zhi; 2014 May; 39(9):1666-9. PubMed ID: 25095381 [TBL] [Abstract][Full Text] [Related]
14. EGFR and MEK Blockade in Triple Negative Breast Cancer Cells. Maiello MR; D'Alessio A; Bevilacqua S; Gallo M; Normanno N; De Luca A J Cell Biochem; 2015 Dec; 116(12):2778-85. PubMed ID: 25959272 [TBL] [Abstract][Full Text] [Related]
15. In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells. Ozbay T; Durden DL; Liu T; O'Regan RM; Nahta R Cancer Chemother Pharmacol; 2010 Mar; 65(4):697-706. PubMed ID: 19636556 [TBL] [Abstract][Full Text] [Related]
16. Silence of α1-Antitrypsin Inhibits Migration and Proliferation of Triple Negative Breast Cancer Cells. Zhao Z; Ma J; Mao Y; Dong L; Li S; Zhang Y Med Sci Monit; 2018 Sep; 24():6851-6860. PubMed ID: 30260937 [TBL] [Abstract][Full Text] [Related]
17. Combined inhibition of the EGFR and mTOR pathways in EGFR wild-type non-small cell lung cancer cell lines with different genetic backgrounds. Huang Y; Chen Y; Mei Q; Chen Y; Yu S; Xia S Oncol Rep; 2013 Jun; 29(6):2486-92. PubMed ID: 23525575 [TBL] [Abstract][Full Text] [Related]
18. Protective effect of hsa-miR-570-3p targeting CD274 on triple negative breast cancer by blocking PI3K/AKT/mTOR signaling pathway. Wang LL; Huang WW; Huang J; Huang RF; Li NN; Hong Y; Chen ML; Wu F; Liu J Kaohsiung J Med Sci; 2020 Aug; 36(8):581-591. PubMed ID: 32311203 [TBL] [Abstract][Full Text] [Related]
19. Gefitinib, a selective EGFR tyrosine kinase inhibitor, induces apoptosis through activation of Bax in human gallbladder adenocarcinoma cells. Ariyama H; Qin B; Baba E; Tanaka R; Mitsugi K; Harada M; Nakano S J Cell Biochem; 2006 Mar; 97(4):724-34. PubMed ID: 16229013 [TBL] [Abstract][Full Text] [Related]
20. 20(S)-Protopanaxadiol-Induced Apoptosis in MCF-7 Breast Cancer Cell Line through the Inhibition of PI3K/AKT/mTOR Signaling Pathway. Zhang H; Xu HL; Wang YC; Lu ZY; Yu XF; Sui DY Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29614812 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]